Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Rivastigmine
Drug ID BADD_D01955
Description Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Indications and Usage For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.
Marketing Status approved; investigational
ATC Code N06DA03
DrugBank ID DB00989
KEGG ID D03822
MeSH ID D000068836
PubChem ID 77991
TTD Drug ID D0WY5Q
NDC Product Code 16714-117; 70710-1198; 72855-101; 0781-7304; 65372-1153; 82245-0107; 51956-0001; 51956-0002; 51991-898; 65162-826; 72855-102; 49706-1825; 0078-0503; 63629-2065; 65162-749; 65162-825; 0378-9072; 0781-7309; 12651-118; 64552-4021; 65015-819; 0078-0501; 63629-8846; 0378-9071; 70710-1196; 16714-115; 63629-2066; 50379-0014; 65862-982; 72855-100; 51956-0003; 51991-897; 51991-899; 0781-7313; 63629-2064; 0378-9070; 0078-0502; 16714-116; 63629-8807; 70710-1197
UNII PKI06M3IW0
Synonyms Rivastigmine | (S)-N-Ethyl-3-((1-dimethyl-amino)ethyl)-N-methylphenylcarbamate | RivastigmineTartrate | Rivastigmine Hydrogen Tartrate | Hydrogen Tartrate, Rivastigmine | Tartrate, Rivastigmine Hydrogen | Exelon | ENA 713 | 713, ENA | SDZ ENA 713 | 713, SDZ ENA | ENA 713, SDZ | ENA-713 | ENA713
Chemical Information
Molecular Formula C14H22N2O2
CAS Registry Number 123441-03-2
SMILES CCN(C)C(=O)OC1=CC=CC(=C1)C(C)N(C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Paralysis17.01.04.0040.000542%Not Available
Paranoia19.05.01.005--Not Available
Parkinsonism17.01.05.0030.000542%Not Available
Pathological fracture16.32.03.007; 15.08.02.008; 12.04.02.006--Not Available
Pemphigoid23.03.01.004; 10.04.02.0020.000542%Not Available
Pemphigus23.03.01.005; 10.04.02.0030.000813%Not Available
Personality disorder19.05.02.002--Not Available
Pleural effusion22.05.02.0020.001897%
Pleurothotonus17.01.03.0090.001084%Not Available
Posture abnormal15.03.05.029; 17.02.05.0330.000542%Not Available
Presyncope02.11.04.013; 24.06.02.010; 17.02.05.0090.000542%
Prostatic disorder21.04.01.001--Not Available
Prurigo23.03.04.0170.000542%Not Available
Pruritus23.03.12.0010.008997%
Psychomotor hyperactivity19.11.02.003; 17.01.02.0110.001355%Not Available
Pulmonary oedema22.01.03.003; 02.05.02.003--
Pyrexia08.05.02.0030.004065%
Rales22.12.01.0110.000542%Not Available
Rash23.03.13.001--Not Available
Rectal haemorrhage24.07.02.018; 07.12.03.001--
Renal cancer20.01.04.002; 16.08.02.0010.000542%Not Available
Renal failure20.01.03.005--Not Available
Respiratory disorder22.02.07.0020.000542%Not Available
Respiratory distress22.02.01.0120.000542%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.001626%
Restlessness19.11.02.002; 17.02.05.0210.001626%
Retching07.01.07.0020.001192%Not Available
Retinal detachment12.01.04.004; 06.09.03.0030.000542%
Salivary hypersecretion07.06.01.0090.001626%Not Available
Sedation17.02.04.0050.000542%Not Available
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 11 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene